Welcome to our dedicated page for Ambrx Biopharma news (Ticker: AMAM), a resource for investors and traders seeking the latest updates and insights on Ambrx Biopharma stock.
Ambrx Biopharma Inc. (NASDAQ: AMAM) is a clinical-stage biotechnology pioneer developing precision antibody-drug conjugates (ADCs) for oncology through its proprietary protein engineering platform. This page serves as the definitive source for AMAM news, providing investors and researchers with timely updates on clinical developments, corporate milestones, and therapeutic innovations.
Access consolidated updates on AMAM's ADC pipeline progress, including Phase 1/2 trials for ARX517 (PSMA-targeting prostate cancer therapy) and ARX788 (HER2-positive cancer treatment). Track strategic partnerships, regulatory filings, and financial disclosures that impact the company's trajectory in the competitive biopharma sector.
Our news collection features verified press releases on clinical trial results, manufacturing advancements, and intellectual property developments. Stay informed about AMAM's expanded genetic code technology applications and their implications for next-generation cancer therapeutics.
Bookmark this page for streamlined access to material events affecting AMAM's market position. Check regularly for updates on ADC platform innovations, peer-reviewed research publications, and executive leadership announcements from this oncology-focused biotech innovator.
Ambrx Biopharma Inc. (NYSE: AMAM) announced that its Chairman, President, and CEO, Feng Tian, Ph.D., will participate in two investor conferences in June. He will engage in a fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit on June 2 at 11:30 AM PT and present at the JMP Securities Life Sciences Conference on June 16 at 11:00 AM PT. Interested parties can access webcasts through the company’s website, with replays available for 90 days. Ambrx focuses on Engineered Precision Biologics, advancing various therapeutic programs, including its lead product candidate ARX788.
Ambrx Biopharma Inc. (NYSE: AMAM) has appointed Dr. Janice Lu as Chief Medical Officer. With over 18 years of experience in clinical trials and breast cancer drug development, Dr. Lu aims to enhance the progress of ARX788 through clinical operations. Her prior roles include Clinical Professor of Medicine at the University of Southern California and Director of Breast Medical Oncology at SUNY Stony Brook. The company focuses on Engineered Precision Biologics and is advancing a strong portfolio of clinical programs.
Ambrx Biopharma Inc. (NYSE: AMAM) has announced that Feng Tian, Ph.D., will present at two investor conferences in May. At the Bank of America 2022 Healthcare Conference, he will participate in a fireside chat on May 11 at 12:00 PM PT. Dr. Tian will also have a pre-recorded presentation at the H.C. Wainwright Global Investment Conference on May 24 at 4:00 AM PT. Interested parties can access the webcasts via www.Ambrx.com. Ambrx focuses on developing Engineered Precision Biologics for various therapeutic areas.
Ambrx Biopharma Inc. (NYSE: AMAM) has filed its annual report on Form 20-F with the SEC for the year ended December 31, 2021. The report, which includes audited consolidated financial statements, is available on both the SEC and company websites. Ambrx utilizes an expanded genetic code technology platform to develop Engineered Precision Biologics, focusing on antibody drug conjugates and immuno-oncology therapies. The company offers a free hard copy of the annual report upon request to shareholders.
Ambrx Biopharma Inc. (NYSE: AMAM) reported a net loss of $68.1 million for the full year ended December 31, 2021, up from $16.5 million in 2020. Revenue decreased to $7.5 million, down from $13.7 million the previous year, primarily due to reduced R&D and licensing revenue. R&D expenses surged to $54.8 million due to increased clinical trial costs, while G&A expenses rose to $17.1 million owing to IPO preparations. Notable advancements include ARX788's participation in I-SPY 2.2 trials and the acceptance of IND for ARX305 by the FDA, with several clinical trials anticipated in 2022.
Ambrx Biopharma (NYSE: AMAM) announces its antibody drug conjugate ARX788 has been selected for the I-SPY 2.2 TRIAL aimed at treating HER2-positive breast cancer. The trial, managed by Quantum Leap Healthcare Collaborative, will evaluate ARX788 as a monotherapy and in combination with cemiplimab. Expected to start patient enrollment in May 2022, the trial seeks to personalize treatment protocols. ARX788 has also received FDA Fast Track Designation for HER2-positive metastatic breast cancer, emphasizing its potential in targeted cancer therapies.
Ambrx Biopharma Inc. (NYSE: AMAM) announced it will release its full year 2021 financial results on
Ambrx Biopharma Inc. (NYSE: AMAM) announced that its CEO, Dr. Feng Tian, will present at the Oppenheimer’s 32nd Annual Healthcare Conference from March 15-17, 2022. Dr. Tian is scheduled to speak on March 17 at 12:40 p.m. Eastern Time. Investors can access the live webcast via the company's website, with a replay available for 90 days post-event. Ambrx focuses on developing Engineered Precision Biologics utilizing an expanded genetic code technology platform, targeting various therapeutic areas including antibody drug conjugates and immuno-oncology.
Ambrx Biopharma Inc. (NYSE: AMAM) announced participation by Dr. Feng Tian, Chairman, President, and CEO, at the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. Dr. Tian will join a corporate panel discussion on ‘Breast Cancer’ on March 9 at 2:10 p.m. Eastern Time. Interested investors can access the live webcast via the company's website, with a replay available for 30 days post-event. Ambrx focuses on developing Engineered Precision Biologics, including next-generation therapies for various diseases.
Ambrx Biopharma Inc. (NYSE: AMAM) has received a "Study May Proceed" letter from the U.S. FDA for its ARX305 Investigational New Drug (IND) application. This anti-CD70 antibody drug conjugate targets various tumors, including renal cell carcinoma. The cleared Phase 1 study aims to evaluate ARX305's safety and preliminary efficacy in patients resistant to standard treatments. This marks Ambrx's third ADC program to advance in clinical development, reflecting their innovative Engineered Precision Biologics platform.
